The transthyretin amyloidoses: From delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug

Steven Johnson, Stephen Connelly, Colleen Fearns, Evan T. Powers, Jeffery W. Kelly

Research output: Contribution to journalReview article

185 Citations (Scopus)

Abstract

Transthyretin (TTR) is one of the many proteins that are known to misfold and aggregate (i.e., undergo amyloidogenesis) in vivo. The process of TTR amyloidogenesis causes nervous system and/or heart pathology. While several of these maladies are associated with mutations that destabilize the native TTR quaternary and/or tertiary structure, wild-type TTR amyloidogenesis also leads to the degeneration of postmitotic tissue. Over the past 20 years, much has been learned about the factors that influence the propensity of TTR to aggregate. This biophysical information led to the development of a therapeutic strategy, termed kinetic stabilization, to prevent TTR amyloidogenesis. This strategy afforded the drug tafamidis which was recently approved by the European Medicines Agency for the treatment of TTR familial amyloid polyneuropathy, the most common familial TTR amyloid disease. Tafamidis is the first and currently the only medication approved to treat TTR familial amyloid polyneuropathy. Here we review the biophysical basis for the kinetic stabilization strategy and the structure-based drug design effort that led to this first-in-class pharmacologic agent.

Original languageEnglish (US)
Pages (from-to)185-203
Number of pages19
JournalJournal of Molecular Biology
Volume421
Issue number2-3
DOIs
StatePublished - Aug 10 2012
Externally publishedYes

Fingerprint

Prealbumin
Pathology
Pharmaceutical Preparations
Familial Amyloid Neuropathies
Amyloidosis, Hereditary, Transthyretin-Related
Drug Design
Amyloid
Nervous System
Mutation

Keywords

  • amyloid
  • kinetic stabilization
  • polyneuropathy
  • transthyretin

ASJC Scopus subject areas

  • Molecular Biology

Cite this

The transthyretin amyloidoses : From delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. / Johnson, Steven; Connelly, Stephen; Fearns, Colleen; Powers, Evan T.; Kelly, Jeffery W.

In: Journal of Molecular Biology, Vol. 421, No. 2-3, 10.08.2012, p. 185-203.

Research output: Contribution to journalReview article

Johnson, Steven ; Connelly, Stephen ; Fearns, Colleen ; Powers, Evan T. ; Kelly, Jeffery W. / The transthyretin amyloidoses : From delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. In: Journal of Molecular Biology. 2012 ; Vol. 421, No. 2-3. pp. 185-203.
@article{abfa05f947ca4c85b7b34a5dfdd53b28,
title = "The transthyretin amyloidoses: From delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug",
abstract = "Transthyretin (TTR) is one of the many proteins that are known to misfold and aggregate (i.e., undergo amyloidogenesis) in vivo. The process of TTR amyloidogenesis causes nervous system and/or heart pathology. While several of these maladies are associated with mutations that destabilize the native TTR quaternary and/or tertiary structure, wild-type TTR amyloidogenesis also leads to the degeneration of postmitotic tissue. Over the past 20 years, much has been learned about the factors that influence the propensity of TTR to aggregate. This biophysical information led to the development of a therapeutic strategy, termed kinetic stabilization, to prevent TTR amyloidogenesis. This strategy afforded the drug tafamidis which was recently approved by the European Medicines Agency for the treatment of TTR familial amyloid polyneuropathy, the most common familial TTR amyloid disease. Tafamidis is the first and currently the only medication approved to treat TTR familial amyloid polyneuropathy. Here we review the biophysical basis for the kinetic stabilization strategy and the structure-based drug design effort that led to this first-in-class pharmacologic agent.",
keywords = "amyloid, kinetic stabilization, polyneuropathy, transthyretin",
author = "Steven Johnson and Stephen Connelly and Colleen Fearns and Powers, {Evan T.} and Kelly, {Jeffery W.}",
year = "2012",
month = "8",
day = "10",
doi = "10.1016/j.jmb.2011.12.060",
language = "English (US)",
volume = "421",
pages = "185--203",
journal = "Journal of Molecular Biology",
issn = "0022-2836",
publisher = "Academic Press Inc.",
number = "2-3",

}

TY - JOUR

T1 - The transthyretin amyloidoses

T2 - From delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug

AU - Johnson, Steven

AU - Connelly, Stephen

AU - Fearns, Colleen

AU - Powers, Evan T.

AU - Kelly, Jeffery W.

PY - 2012/8/10

Y1 - 2012/8/10

N2 - Transthyretin (TTR) is one of the many proteins that are known to misfold and aggregate (i.e., undergo amyloidogenesis) in vivo. The process of TTR amyloidogenesis causes nervous system and/or heart pathology. While several of these maladies are associated with mutations that destabilize the native TTR quaternary and/or tertiary structure, wild-type TTR amyloidogenesis also leads to the degeneration of postmitotic tissue. Over the past 20 years, much has been learned about the factors that influence the propensity of TTR to aggregate. This biophysical information led to the development of a therapeutic strategy, termed kinetic stabilization, to prevent TTR amyloidogenesis. This strategy afforded the drug tafamidis which was recently approved by the European Medicines Agency for the treatment of TTR familial amyloid polyneuropathy, the most common familial TTR amyloid disease. Tafamidis is the first and currently the only medication approved to treat TTR familial amyloid polyneuropathy. Here we review the biophysical basis for the kinetic stabilization strategy and the structure-based drug design effort that led to this first-in-class pharmacologic agent.

AB - Transthyretin (TTR) is one of the many proteins that are known to misfold and aggregate (i.e., undergo amyloidogenesis) in vivo. The process of TTR amyloidogenesis causes nervous system and/or heart pathology. While several of these maladies are associated with mutations that destabilize the native TTR quaternary and/or tertiary structure, wild-type TTR amyloidogenesis also leads to the degeneration of postmitotic tissue. Over the past 20 years, much has been learned about the factors that influence the propensity of TTR to aggregate. This biophysical information led to the development of a therapeutic strategy, termed kinetic stabilization, to prevent TTR amyloidogenesis. This strategy afforded the drug tafamidis which was recently approved by the European Medicines Agency for the treatment of TTR familial amyloid polyneuropathy, the most common familial TTR amyloid disease. Tafamidis is the first and currently the only medication approved to treat TTR familial amyloid polyneuropathy. Here we review the biophysical basis for the kinetic stabilization strategy and the structure-based drug design effort that led to this first-in-class pharmacologic agent.

KW - amyloid

KW - kinetic stabilization

KW - polyneuropathy

KW - transthyretin

UR - http://www.scopus.com/inward/record.url?scp=84861421529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861421529&partnerID=8YFLogxK

U2 - 10.1016/j.jmb.2011.12.060

DO - 10.1016/j.jmb.2011.12.060

M3 - Review article

C2 - 22244854

AN - SCOPUS:84861421529

VL - 421

SP - 185

EP - 203

JO - Journal of Molecular Biology

JF - Journal of Molecular Biology

SN - 0022-2836

IS - 2-3

ER -